Can an experimental drug reduce eye bulging in thyroid eye disease?

NCT ID NCT07720648

First seen Jul 22, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This phase 3 trial is testing whether the experimental drug KHN939 can reduce eye bulging in people with moderate-to-severe inactive thyroid eye disease. About 117 participants in China will receive either KHN939 or a placebo by infusion every three weeks for 21 weeks. The main goal is to see if the drug leads to a meaningful reduction in eye protrusion without worsening the other eye.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental drug called KHN939
What this could lead to
If it works, this could offer a new treatment option for thyroid eye disease, potentially reducing eye bulging and improving quality of life.
What could go wrong
This is an early-phase trial in a specific population (Chinese patients with inactive disease). The drug may not work as hoped or could cause side effects. Results may not apply to other groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endocrine exophthalmos Graves Ophthalmopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

    Shanghai, Shanghai Municipality, 200135, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.